Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia
Avadel Pharmaceuticals plc, a biopharmaceutical company focused on transforming medicines to transform lives, announced on June 5 2025, that LUMRYZTM ...